MedTrace Logo

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

NCT00083174 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4560

Last updated 2023-08-25

Study results available
· View outcomes & findings →

Summary

RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may prevent breast cancer by blocking the production of estrogen.

PURPOSE: The study protocol was amended in May 2011 and the current purpose of the study is to allow all study participants the opportunity to complete 5 years of exemestane.

Conditions

Interventions

DRUG

exemestane

one 25 mg tablet daily in am

Sponsors & Collaborators

  • Grupo Espanol de Investigacion del Cancer de Mama

    collaborator OTHER

  • UNICANCER

    collaborator OTHER

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Paul E. Goss, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-12-03
Primary Completion
2011-03-25
Completion
2018-01-22
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00083174 on ClinicalTrials.gov